Does the media refer more to BMY or AMGN?

In the previous week, Amgen had 21 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 59 mentions for Amgen and 38 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 0.92 beat Amgen's score of 0.42 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 24 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 23 Very Positive mention(s) 6 Positive mention(s) 15 Neutral mention(s) 11 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media favor EXEL or BMY?

In the previous week, Bristol Myers Squibb had 17 more articles in the media than Exelixis. MarketBeat recorded 38 mentions for Bristol Myers Squibb and 21 mentions for Exelixis. Exelixis' average media sentiment score of 1.00 beat Bristol Myers Squibb's score of 0.92 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 24 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to BMY or GILD?

In the previous week, Gilead Sciences had 3 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 41 mentions for Gilead Sciences and 38 mentions for Bristol Myers Squibb. Gilead Sciences' average media sentiment score of 1.04 beat Bristol Myers Squibb's score of 0.92 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 24 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Gilead Sciences 26 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer BMY or VRTX?

In the previous week, Bristol Myers Squibb had 19 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 38 mentions for Bristol Myers Squibb and 19 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat Bristol Myers Squibb's score of 0.92 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 24 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Vertex Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer ABBV or BMY?

In the previous week, AbbVie had 96 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 134 mentions for AbbVie and 38 mentions for Bristol Myers Squibb. AbbVie's average media sentiment score of 1.39 beat Bristol Myers Squibb's score of 0.92 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 109 Very Positive mention(s) 9 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive Bristol Myers Squibb 24 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Bristol Myers Squibb (BMY) Competitors

$64.46 -0.23 (-0.35%)

Closing price 03:59 PM Eastern

Extended Trading

$64.76 +0.30 (+0.46%)

As of 05:05 PM Eastern

Compare

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

Should you buy Bristol Myers Squibb stock or one of its competitors? Bristol Myers Squibb's main competitors and comparable companies include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Bristol Myers Squibb compare to Amgen?

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Bristol Myers Squibb presently has a consensus target price of $66.06, indicating a potential upside of 2.47%. Amgen has a consensus target price of $381.68, indicating a potential downside of 2.45%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, research analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Amgen	3 Sell rating(s)	14 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.37

In the previous week, Amgen had 21 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 59 mentions for Amgen and 38 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 0.92 beat Amgen's score of 0.42 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	24 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	23 Very Positive mention(s)	6 Positive mention(s)	15 Neutral mention(s)	11 Negative mention(s)	3 Very Negative mention(s)	Neutral

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$49.19B	2.68	$7.05B	$4.54	14.20
Amgen	$36.75B	5.76	$7.71B	$16.09	24.32

Bristol Myers Squibb has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.9%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.6%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Amgen has increased its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a net margin of 22.95% compared to Bristol Myers Squibb's net margin of 18.87%. Amgen's return on equity of 124.14% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Amgen	22.95%	124.14%	13.18%

Summary

Amgen beats Bristol Myers Squibb on 10 of the 19 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Bristol Myers Squibb had 17 more articles in the media than Exelixis. MarketBeat recorded 38 mentions for Bristol Myers Squibb and 21 mentions for Exelixis. Exelixis' average media sentiment score of 1.00 beat Bristol Myers Squibb's score of 0.92 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	24 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

85.3% of Exelixis shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 14.17%. Bristol Myers Squibb has a consensus price target of $66.06, suggesting a potential upside of 2.47%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56

Bristol Myers Squibb has higher revenue and earnings than Exelixis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.93	$782.57M	$3.18	18.34
Bristol Myers Squibb	$49.19B	2.68	$7.05B	$4.54	14.20

Exelixis has a net margin of 35.33% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Bristol Myers Squibb	18.87%	66.90%	14.74%

Summary

Exelixis and Bristol Myers Squibb tied by winning 8 of the 16 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Gilead Sciences?

Bristol Myers Squibb (NYSE:BMY) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Bristol Myers Squibb presently has a consensus target price of $66.06, suggesting a potential upside of 2.47%. Gilead Sciences has a consensus target price of $158.04, suggesting a potential upside of 8.50%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86

Bristol Myers Squibb has a net margin of 18.87% compared to Gilead Sciences' net margin of -10.64%. Bristol Myers Squibb's return on equity of 66.90% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Gilead Sciences	-10.64%	-2.11%	-0.75%

In the previous week, Gilead Sciences had 3 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 41 mentions for Gilead Sciences and 38 mentions for Bristol Myers Squibb. Gilead Sciences' average media sentiment score of 1.04 beat Bristol Myers Squibb's score of 0.92 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	24 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Gilead Sciences	26 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.9%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.3%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has lower revenue, but higher earnings than Bristol Myers Squibb. Gilead Sciences is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$49.19B	2.68	$7.05B	$4.54	14.20
Gilead Sciences	$29.44B	6.13	$8.51B	-$2.67	N/A

Bristol Myers Squibb has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Summary

Gilead Sciences beats Bristol Myers Squibb on 11 of the 19 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Bristol Myers Squibb (NYSE:BMY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Bristol Myers Squibb had 19 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 38 mentions for Bristol Myers Squibb and 19 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat Bristol Myers Squibb's score of 0.92 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	24 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Bristol Myers Squibb has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Bristol Myers Squibb currently has a consensus target price of $66.06, indicating a potential upside of 2.47%. Vertex Pharmaceuticals has a consensus target price of $569.52, indicating a potential upside of 9.29%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96

Bristol Myers Squibb has higher revenue and earnings than Vertex Pharmaceuticals. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$49.19B	2.68	$7.05B	$4.54	14.20
Vertex Pharmaceuticals	$12.59B	10.51	$3.95B	$17.18	30.33

Summary

Vertex Pharmaceuticals beats Bristol Myers Squibb on 12 of the 16 factors compared between the two stocks.

How does Bristol Myers Squibb compare to AbbVie?

AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.9%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Bristol Myers Squibb has lower revenue, but higher earnings than AbbVie. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.25	$4.23B	$3.54	70.91
Bristol Myers Squibb	$49.19B	2.68	$7.05B	$4.54	14.20

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bristol Myers Squibb has a net margin of 18.87% compared to AbbVie's net margin of 9.80%. Bristol Myers Squibb's return on equity of 66.90% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Bristol Myers Squibb	18.87%	66.90%	14.74%

In the previous week, AbbVie had 96 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 134 mentions for AbbVie and 38 mentions for Bristol Myers Squibb. AbbVie's average media sentiment score of 1.39 beat Bristol Myers Squibb's score of 0.92 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	109 Very Positive mention(s)	9 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Bristol Myers Squibb	24 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

AbbVie currently has a consensus price target of $275.95, indicating a potential upside of 9.92%. Bristol Myers Squibb has a consensus price target of $66.06, indicating a potential upside of 2.47%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56

AbbVie has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Summary

AbbVie beats Bristol Myers Squibb on 12 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bristol Myers Squibb	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$131.68B	$12.39B	$7.13B	$23.28B
Dividend Yield	3.77%	2.59%	2.54%	3.73%
P/E Ratio	14.20	794.77	272.37	28.72
Price / Sales	2.68	756.53	696.29	95.66
Price / Cash	8.22	90.26	77.07	33.53
Price / Book	7.09	10.56	10.75	4.75
Net Income	$7.05B	$2.82B	$3.48B	$1.07B
7 Day Performance	-4.58%	-2.24%	-1.35%	-0.95%
1 Month Performance	-0.26%	2.49%	2.22%	-2.29%
1 Year Performance	36.43%	4.83%	20.76%	11.70%

Bristol Myers Squibb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bristol Myers Squibb	4.7003 of 5 stars	$64.46 -0.4%	$66.06 +2.5%	+38.4%	$131.68B	$49.19B	14.20	32,500
AMGN Amgen	3.9299 of 5 stars	$444.12 +0.3%	$380.43 -14.3%	+40.3%	$239.41B	$38.10B	27.60	31,500	Trending News Analyst Forecast
EXEL Exelixis	3.0616 of 5 stars	$59.13 +1.0%	$50.07 -15.3%	+53.0%	$14.50B	$2.32B	18.59	1,077	Analyst Revision
GILD Gilead Sciences	3.8705 of 5 stars	$151.22 +1.1%	$158.04 +4.5%	+26.5%	$185.51B	$30.46B	N/A	17,000	Positive News
VRTX Vertex Pharmaceuticals	3.8306 of 5 stars	$557.96 +0.2%	$569.52 +2.1%	+33.8%	$141.31B	$12.00B	32.48	6,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BMY) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Do analysts rate BMY or AMGN?

Does the media refer more to BMY or AMGN?

Do institutionals and insiders believe in BMY or AMGN?

Which has higher valuation and earnings, BMY or AMGN?

Which has more volatility and risk, BMY or AMGN?

Is BMY or AMGN a better dividend stock?

Is BMY or AMGN more profitable?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Does the media favor EXEL or BMY?

Do insiders and institutionals believe in EXEL or BMY?

Which has more volatility & risk, EXEL or BMY?

Do analysts rate EXEL or BMY?

Which has preferable earnings & valuation, EXEL or BMY?

Is EXEL or BMY more profitable?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Do analysts rate BMY or GILD?

Is BMY or GILD more profitable?

Does the media refer more to BMY or GILD?

Do insiders & institutionals have more ownership in BMY or GILD?

Is BMY or GILD a better dividend stock?

Which has better valuation & earnings, BMY or GILD?

Which has more risk & volatility, BMY or GILD?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Is BMY or VRTX more profitable?

Do insiders and institutionals have more ownership in BMY or VRTX?

Does the media prefer BMY or VRTX?

Which has more risk & volatility, BMY or VRTX?

Do analysts recommend BMY or VRTX?

Which has better valuation & earnings, BMY or VRTX?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Is ABBV or BMY a better dividend stock?

Which has better earnings & valuation, ABBV or BMY?

Do insiders and institutionals have more ownership in ABBV or BMY?

Is ABBV or BMY more profitable?

Does the media prefer ABBV or BMY?

Do analysts recommend ABBV or BMY?

Which has more risk & volatility, ABBV or BMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools